Production (Stage)
BioRestorative Therapies, Inc.
BRTX
$1.66
$0.063.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -28.57% | 124.35% | 660.91% | 38.14% | 11.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.57% | 124.35% | 660.91% | 38.14% | 11.82% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -36.86% | 107.25% | 601.63% | 28.06% | 11.82% |
| SG&A Expenses | 0.95% | -50.14% | -49.15% | -44.73% | -32.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.61% | -15.64% | -19.60% | -19.59% | -28.67% |
| Operating Income | -16.99% | 16.47% | 26.33% | 20.79% | 28.89% |
| Income Before Tax | -140.17% | 28.99% | -122.89% | 29.44% | 69.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -140.17% | 28.99% | -122.89% | 29.44% | 69.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.17% | 28.99% | -122.89% | 29.44% | 69.00% |
| EBIT | -16.99% | 16.47% | 26.33% | 20.79% | 28.89% |
| EBITDA | -16.95% | 16.94% | 26.89% | 21.27% | 29.15% |
| EPS Basic | -91.72% | 59.02% | -112.88% | 66.24% | 82.73% |
| Normalized Basic EPS | -91.69% | 101.89% | -112.88% | 66.24% | 82.73% |
| EPS Diluted | -91.72% | 58.90% | -112.92% | 65.99% | 82.73% |
| Normalized Diluted EPS | -91.69% | 101.89% | -112.88% | 66.24% | 82.73% |
| Average Basic Shares Outstanding | 25.27% | 73.34% | 77.68% | 108.98% | 79.46% |
| Average Diluted Shares Outstanding | 25.27% | 73.34% | 77.68% | 108.98% | 79.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |